Hansa Medical to present at The Oppenheimer 27th Annual Healthcare Conference

Hansa Medical will present at the Oppenheimer 27th Annual Healthcare Conference on March 21 in New York City. Göran Arvidson, Chief Executive Officer, will present at the conference at 8:35 a.m. EST. (2:35 p.m. CET)

A live audio webcast of the presentation will be accessible through the Hansa Medical website www.hansamedical.com and through the following link: https://www.veracast.com/webcasts/opco/healthcare2017/33101593658.cfm  

This information is information that Hansa Medical AB (publ) is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 08:00 CET on March 8, 2017.  

For further information, please contact:
Hansa Medical AB (Publ)
Emanuel Björne, Vice President Business Development and Investor Relations
Mobil: +46707175477
E-mail: emanuel.bjorne@hansamedical.com

Cord Communications, Stockholm
Mikael Widell
Mobile: +46 70 311 9960

Lars Wahlström
Mobile: +46 73 434 0771

FTI Consulting, London
Julia Phillips / Stephanie Cuthbert / Hanna Skeppner: +44 203 727 1000

About Hansa Medical AB
Hansa Medical is a biopharmaceutical company focusing on novel immunomodulatory enzymes. The lead project IdeS is a proprietary antibody-degrading enzyme in clinical development, with potential use in transplantation and rare autoimmune diseases. Additional projects focus on development of new antibody modulating enzymes, as well as HBP, a diagnostic biomarker for prediction of severe sepsis at emergency departments that is already introduced on the market. The company is based in Lund, Sweden. Hansa Medical’s share (ticker: HMED) is listed on Nasdaq Stockholm.

Tags:

About Us

Hansa Medical is a biopharmaceutical company focused on novel immunomodulatory enzymes. Lead project IdeS is an antibody-degrading enzyme in clinical development, with potential use in transplantation and rare autoimmune diseases. Other projects include HBP (a market introduced diagnostic marker for severe sepsis) and EndoS (an antibody-modulating bacterial enzyme in pre-clinical development). The company is based in Lund, Sweden. Hansa Medical's share (HMED) is listed on Nasdaq First North in Stockholm with Remium Nordic AB as Certified Adviser.